Muscarinic M3 positive allosteric modulator ASP8302 enhances bladder contraction and improves voiding dysfunction in rats

Muscarinic M3 (M3) receptors mediate cholinergic smooth muscle contraction of the bladder. Current drugs targeting bladder M3 receptors for micturition disorders have a risk of cholinergic side effects due to excessive receptor activation and insufficient selectivity. We investigated the effect of ASP8302, a novel positive allosteric modulator (PAM) of M3 receptors, on bladder function in rats.

• Publication year

  2022

• Venue

  Lower urinary tract symptoms

• Publication date

  2022-02-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/luts.12430PMID 35150075
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Design, Synthesis, and Structure-Activity Relationships Study of N-Pyrimidyl/Pyridyl-2-thiazolamine Analogues as Novel Positive Allosteric Modulators of M3 Muscarinic Acetylcholine Receptor.

  2021cited by this paper
• Potentiation of Muscarinic M3 Receptor Activation through a New Allosteric Site with a Novel Positive Allosteric Modulator ASP8302

  2021cited by this paper
• Clinical diagnostic criteria for detrusor underactivity: A report from the Japanese Continence Society working group on underactive bladder

  2020cited by this paper
• Discovery and structure-activity relationships study of positive allosteric modulators of the M3 muscarinic acetylcholine receptor.

  2020cited by this paper
• Urethral dysfunction and therapeutic effects of a PDE 5 inhibitor (tadalafil) in a rat model of detrusor underactivity induced by pelvic nerve crush injury

  2020cited by this paper
• ASP6432, a type 1 lysophosphatidic acid receptor antagonist, reduces urethral function during urine voiding and improves voiding dysfunction

  2019cited by this paper
• Pathophysiological mechanisms in detrusor underactivity: Novel experimental findings

  2019cited by this paper
• Toward an understanding of the structural basis of allostery in muscarinic acetylcholine receptors

  2018cited by this paper
• Terminology report from the International Continence Society (ICS) Working Group on Underactive Bladder (UAB)

  2018cited by this paper
• Pathophysiology of the underactive bladder

  2017cited by this paper
• Effects of the phosphodiesterase 5 inhibitor Tadalafil on bladder function in a rat model of partial bladder outlet obstruction

  2016cited by this paper
• Effect of Selective Prostaglandin E2 EP2 Receptor Agonist CP‐533,536 on Voiding Efficiency in Rats with Midodrine‐Induced Functional Urethral Obstruction

  2016cited by this paper
• Muscarinic regulation of dopamine and glutamate transmission in the nucleus accumbens

  2015cited by this paper
• Pathophysiology and animal modeling of underactive bladder

  2014cited by this paper
• Detrusor underactivity and the underactive bladder: a new clinical entity? A review of current terminology, definitions, epidemiology, aetiology, and diagnosis.

  2014cited by this paper
• Effects of chronic treatment with cilostazol, a phosphodiesterase 3 inhibitor, on female rat bladder in a partial bladder outlet obstruction model.

  2014cited by this paper
• Activation and allosteric modulation of a muscarinic acetylcholine receptor

  2013cited by this paper
• Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs

  2013cited by this paper
• Muscarinic agonists and antagonists: effects on the urinary bladder.

  2012cited by this paper
• Allosteric Modulation of the M3 Muscarinic Receptor by Amiodarone and N-Ethylamiodarone: Application of the Four-Ligand Allosteric Two-State Model

  2011cited by this paper
• Detrusor underactivity: A plea for new approaches to a common bladder dysfunction

  2011cited by this paper
• Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders

  2009cited by this paper
• The neural control of micturition

  2008cited by this paper
• Is the use of parasympathomimetics for treating an underactive urinary bladder evidence‐based?

  2007cited by this paper
• Mechanisms underlying the recovery of lower urinary tract function following spinal cord injury.

  2006cited by this paper
• Cystometric findings in mice lacking muscarinic M2 or M3 receptors.

  2004cited by this paper
• Mice Lacking M2 and M3 Muscarinic Acetylcholine Receptors Are Devoid of Cholinergic Smooth Muscle Contractions But Still Viable

  2002cited by this paper
• SELECTIVE STIMULATION OF PIG RADIAL NERVE: COMPARISON OF 12-POLAR AND 18-POLAR CUFF ELECTRODES

  2002cited by this paper
• Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia

  2002cited by this paper
• M3 muscarinic receptors mediate contraction of human urinary bladder

  2002cited by this paper
• M(3) muscarinic receptors mediate contraction of human urinary bladder.

  2002cited by this paper
• Symptomatic and urodynamic improvement by oral distigmine bromide in poor voiders after transurethral resection of the prostate.

  2001cited by this paper
• Brain-Stimulation Reward Thresholds Raised by an Antisense Oligonucleotide for the M5 Muscarinic Receptor Infused near Dopamine Cells

  2000cited by this paper
• Absolute bioavailability, pharmacokinetics, renal and biliary clearance of distigmine after a single oral dose in comparison to i.v. administration of 14C-distigmine-bromide in healthy volunteers.

  1999cited by this paper
• Selective detrusor activation by electrical stimulation of the human sacral nerve roots.

  1997cited by this paper
• Pharmacological characterization of the muscarinic receptor subtypes responsible for the contractile response in the rat urinary bladder.

  1997cited by this paper
• Mechanical responses of the rat uterus, cervix, and bladder to stimulation of hypogastric and pelvic nerves in vivo.

  1989cited by this paper
• Effects of atropine on bladder capacity and instability in rats with bladder hypertrophy

  1987cited by this paper

• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Muscarinic M3 Receptor‐Positive Allosteric Modulator ASP8302 Following Single and Multiple Ascending Oral Doses in Healthy Volunteers

  2024cites this paper